Uptake rate of cationic mitochondrial inhibitor MKT-077 determines cellular oxygen consumption change in carcinoma cells

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Chunta, John L ^a,b   Vistisen, Kerry S ^a   Yazdi, Zeinab ^a   Braun, Rod D ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CELL LEVEL; CELL MEMBRANE POTENTIAL; CELL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MATHEMATICAL ANALYSIS; METABOLIC INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TENSION; POLAROGRAPHY; RADIOSENSITIVITY; RAT; SPECTROSCOPY; TRANSPORT KINETICS; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; KINETICS; MATHEMATICAL PHENOMENA; METABOLISM; MITOCHONDRION; TUMOR CELL LINE;

RATTUS;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; KINETICS; MAMMARY NEOPLASMS, ANIMAL; MATHEMATICAL CONCEPTS; MITOCHONDRIA; OXYGEN CONSUMPTION; PYRIDINES; RATS; THIAZOLES;

EID: 84861211155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037471     Document Type: Article

References (37)

1. Höckel M, Vaupel P, (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276.
2. Gray LJ, Conger AD, Ebert M, Hornsey S, Scott OCA, (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648.
3. Thomlinson RH, Gray LH, (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549.
4. Hall E, Giaccia AJ, (2006) Radiobiology for the radiologist Philadelphia, USA Lippincott Wilkins & Williams.
5. Okunieff P, de Bie J, Dunphy EP, Terris DJ, Hockel M, (1996) Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. Br J Cancer Suppl 27: S185-190.
6. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, et al. (1993) Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26: 631-636.
7. Overgaard J, (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25: 4066-4074.
8. Secomb TW, Hsu R, Braun RD, Ross JR, Gross JF, et al. (1998) Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol 454: 629-634.
9. Secomb TW, Hsu R, Dewhirst MW, Klitzman B, Gross JF, (1993) Analysis of oxygen transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys 25: 481-489.
10. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW, (1995) Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34: 313-316.
11. Crokart N, Jordan BF, Baudelet C, Cron GO, Hotton J, et al. (2007) Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res 13: 630-635.
12. Chiba Y, Kubota T, Watanabe M, Matsuzaki SW, Otani Y, et al. (1998) MKT-077, localized lipophilic cation: antitumor activity against human tumor xenografts serially transplanted into nude mice. Anticancer Res 18: 1047-1052.
13. Chiba Y, Kubota T, Watanabe M, Otani Y, Teramoto T, et al. (1998) Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro. J Surg Oncol 69: 105-110.
14. Chiba Y, Kubota T, Watanabe M, Yoshihide O, Teramoto T, et al. (1999) Antitumor activity of delocalized lipophilic cation, MKT-077 in human carcinomas obtained from fresh surgical specimens. Int J Clin Oncol 4: 65-68.
15. Koya K, Li Y, Wang H, Ukai T, Tatsuta N, et al. (1996) MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 56: 538-543.
16. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, et al. (1996) Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 56: 544-550.
17. Tatsuta N, Suzuki N, Mochizuki T, Koya K, Kawakami M, et al. (1999) Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent. Cancer Chemother Pharmacol 43: 295-301.
18. Weisberg EL, Koya K, Modica-Napolitano J, Li Y, Chen LB, (1996) In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res 56: 551-555.
19. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, et al. (2000) A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 6: 42-49.
20. Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, et al. (1999) Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann Oncol 10: 923-927.
21. Hilf R, Michel I, Bell C, Freeman JJ, Borman A, (1965) Biochemical and morphologic properties of a new lactating mammary tumor line in the rat. Cancer Res 25: 286-299.
22. Cailleau R, Olive M, Cruciger QV, (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915.
23. Louis KS, Siegel AC, (2011) Cell viability analysis using trypan blue: manual and automated methods. Methods Mol Biol 740: 7-12.
24. Modica-Napolitano JS, Brunelli BT, Koya K, Chen LB, (1998) Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077. Cancer Res 58: 71-75.
25. Goldman DE, (1943) Potential, impedance, and rectification in membranes. J Gen Physiol 27: 37-60.
26. Emri M, Balkay L, Krasznai Z, Trón L, Márián T, (1998) Wide applicability of a flow cytometric assay to measure absolute membrane potentials on the millivolt scale. Eur Biophys J 28: 78-83.
27. Posakony JW, England JM, Attardi G, (1977) Mitochondrial growth and division during the cell cycle in HeLa cells. J Cell Biol 74: 468-491.
28. Goldstick TK, (1973) Oxygen transport. In: Brown JHU, Gann DS, editors. Engineering Principles in Physiology New York Academic Press pp. 257-282.
29. Loetchutinat C, Saengkhae C, Marbeuf-Gueye C, Garnier-Suillerot A, (2003) New insights into the P-glycoprotein-mediated effluxes of rhodamines. Eur J Biochem 270: 476-485.
30. Tikoo A, Shakri R, Connolly L, Hirokawa Y, Shishido T, et al. (2000) Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077. Cancer J Sci Am 6: 162-168.
31. Naasani I, Seimiya H, Yamori T, Tsuruo T, (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59: 4004-4011.
32. Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, et al. (2007) Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett 252: 259-269.
33. Kaul SC, Reddel RR, Mitsui Y, Wadhwa R, (2001) An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia 3: 110-114.
34. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, et al. (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60: 6818-6821.
35. Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers RN, et al. (2000) Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res Commun 275: 174-179.
36. Nuydens R, Novalbos J, Dispersyn G, Weber C, Borgers M, et al. (1999) A rapid method for the evaluation of compounds with mitochondria-protective properties. J Neurosci Methods 92: 153-159.
37. Schumacker PT, Chandel N, Agusti AG, (1993) Oxygen conformance of cellular respiration in hepatocytes. Am J Physiol 265: L395-402.